KR20190088207A - Composition for treating hair loss and promoting hair growth - Google Patents
Composition for treating hair loss and promoting hair growth Download PDFInfo
- Publication number
- KR20190088207A KR20190088207A KR1020180006439A KR20180006439A KR20190088207A KR 20190088207 A KR20190088207 A KR 20190088207A KR 1020180006439 A KR1020180006439 A KR 1020180006439A KR 20180006439 A KR20180006439 A KR 20180006439A KR 20190088207 A KR20190088207 A KR 20190088207A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hair
- hair loss
- present
- broiler
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 63
- 208000024963 hair loss Diseases 0.000 title claims abstract description 58
- 230000003676 hair loss Effects 0.000 title claims abstract description 58
- 230000003779 hair growth Effects 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 84
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 8
- 241000605072 Cinnamomum verum Species 0.000 claims abstract description 6
- 235000021512 Cinnamomum verum Nutrition 0.000 claims abstract description 5
- 241000287828 Gallus gallus Species 0.000 claims description 47
- 235000006533 astragalus Nutrition 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 12
- 210000003780 hair follicle Anatomy 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 6
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 3
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 3
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 3
- 230000000284 resting effect Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000034557 congenital alopecia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 38
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 description 27
- 230000000694 effects Effects 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 239000013642 negative control Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 4
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000723353 Chrysanthemum Species 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- -1 troches Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 244000144987 brood Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000008989 cinnamomi cortex Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WOYWLLHHWAMFCB-UHFFFAOYSA-N 2-ethylhexyl acetate Chemical compound CCCCC(CC)COC(C)=O WOYWLLHHWAMFCB-UHFFFAOYSA-N 0.000 description 1
- GNQSEISTGYFZSL-UHFFFAOYSA-N 3-hydroxy-2-imino-6-phenoxypyrimidin-4-amine Chemical compound N=C1N(O)C(N)=CC(OC=2C=CC=CC=2)=N1 GNQSEISTGYFZSL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000266855 Astragalus mongholicus Species 0.000 description 1
- 241000790026 Astragalus uliginosus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 244000037185 Cinnamomum burmannii Species 0.000 description 1
- 235000014487 Cinnamomum burmannii Nutrition 0.000 description 1
- 241000252804 Cinnamomum insularimontanum Species 0.000 description 1
- 235000002428 Cinnamomum japonicum Nutrition 0.000 description 1
- 241001350919 Cinnamomum loureiroi Species 0.000 description 1
- 241000252806 Cinnamomum sieboldii Species 0.000 description 1
- 241000107513 Cinnamomum subavenium Species 0.000 description 1
- 241000917739 Cinnamomum wilsonii Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- KUQCZABKHLILRI-UHFFFAOYSA-M sodium;2,2-dihydroxyacetate Chemical compound [Na+].OC(O)C([O-])=O KUQCZABKHLILRI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003135 vibrissae Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 탈모의 예방, 개선 또는 치료용 약제학적 조성물 및 식품 조성물, 그리고 발모 촉진용 조성물에 대한 것이다.The present invention relates to a pharmaceutical composition and a food composition for preventing, ameliorating or treating hair loss, and a hair growth promoting composition.
탈모란 정상적으로 모발이 있어야 할 곳에 모발이 없는 상태를 말하며 유전적 요인이 주요한 원인으로 알려져 있다. 최근에는 사회적 스트레스의 증가와 더불어 환경오염 및 인스턴트 식품 등 서구화된 식습관, 잦은 파마와 염색, 잘못된 두피관리들로 인하여 탈모 인구가 점차 증가하고 있는 추세이다. 그러나 아직까지 탈모에 대한 명확한 원인은 규명되고 있지 않고, 최근 들어 오히려 탈모증으로 고민하는 사람이 점점 늘고 있으며 그 연령층도 낮아지고 있는 실정이다. Hair loss refers to a condition where hair normally does not have hair where it should be, and genetic factors are known to be the main cause. In recent years, with the increase of social stress, hair loss population is gradually increasing due to westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing, and wrong scalp care. However, the cause of hair loss has not yet been clarified yet. Recently, more and more people are suffering from alopecia, and the age group is lowering.
탈모증의 치료법에 관해서도 아직까지 뚜렷한 효과를 지닌 것은 없으며, 동의보감에서는 신응양진단 등 탈모에 관계되는 몇몇 복용하는 처방들이 있고, 호마유(참깨) 등을 탈모 부위에 마사지한다든지, 특정 한약처방을 주침해서 바르는 방법과 특정 혈위를 자극하는 방법 등이 있지만 효과에 있어서는 개인적 차이가 많다고 알려져 있다. There are no clear effects on the treatment of alopecia, and there are some prescriptions for taking hair loss, such as diagnosis of newborns in Dong-bo-gyung, and massage of sesame seeds on hair loss site, It is known that there are many individual differences in the effects, such as how to apply and how to stimulate specific blood circulation.
종래의 탈모증 치료방법으로는, 호르몬설과 관련하여 여성 호르몬을 주재로 한 제제가 있으나 피부 염증 발생, 호르몬 투여에 의한 부작용 발생 등의 보고가 있어 현재는 사용이 중단되고 있다. 최근 사용되고 있는 대표적인 발모제로는, 처음에는 혈액 순환 촉진을 위한 용도로 개발되어 사용되다가 이를 사용하는 환자들 사이에서 부작용으로 발모 효과를 나타내는 것으로 알려져, 이후, 발모용 원료로 미국식품의약품안전청(FDA)에서 승인받아 발모 치료제로 사용되고 있는 미국특허 제3,382,247호의 미녹시딜(6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine)및 미국특허 제 5,215,894 호에서 언급된 머크사의 피나스테라이드(finasteride)가 있다. As a conventional method for treating alopecia, there is a preparation based on female hormone in relation to hormonal theory, but there are reports of occurrence of skin inflammation and side effects due to administration of hormone, and the use thereof is stopped at present. It is known that the hair growth inhibitory effect is caused by side effects among patients who have been developed and used for promotion of blood circulation at first, and then the US Food and Drug Administration (FDA) 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine of U.S. Patent No. 3,382,247, which has been approved by the US Patent No. 5,215,894, finasteride.
그러나, 미녹시딜의 경우 끈적이는 사용감과 피부에 자극을 유발하는 부작용이 보고된 바 있으며, 피나스테라이드의 경우 현재 경구 투여용 제제로 사용되고 있으나, 이의 섭취에 따라 성기능 장애 등의 부작용이 보고된 일도 있을 뿐 아니라, 탈모에 대해서도 꾸준한 복용이 이루어져야만 효과가 있다는 단점이 있다. However, minoxidil has been reported to have a sticky feel and side effects that cause irritation to the skin. In the case of pinasteride, it is currently used as a preparation for oral administration. However, adverse effects such as sexual dysfunction have been reported depending on its consumption, There is also a disadvantage in that it is effective only if the hair loss is steadily taken.
따라서, 기존 약물의 부작용을 개선할 수 있는 새로운 약물에 대한 요구는 꾸준히 늘어나고 있다.Therefore, the demand for new drugs that can improve the side effects of existing drugs is steadily increasing.
한편, 육계(Cinnamomi Cortex)는 녹나무과(Lauraceae)에 속하는 육계나무(Cinnamomum cassia) 또는 그밖의 동속 근연식물의 줄기껍질로, 주피를 다소 제거하여 사용하기도 한다. 육계는 통 모양 또는 말려 들어간 통 모양이고, 길이 5 cm 내지 50 cm, 지름 1.5 cm 내지 5 cm, 두께 0.1 cm 내지 0.5 cm이다. 바깥 면은 어두운 적갈색, 안쪽 면은 적갈색을 띠며 매끈하다. 꺾이기 쉬우며 꺾인 면은 적갈색을 띠고 연한 갈색의 얇은 층이 있으며 약간 섬유성이다. On the other hand, broiler (Cinnamomi Cortex) is a stem shell of Cinnamomum cassia or other related plants belonging to the family Lauraceae. The broiler chickens are tubular or barrel-shaped, with a length of 5 cm to 50 cm, a diameter of 1.5 cm to 5 cm, and a thickness of 0.1 cm to 0.5 cm. Outer surface is dark reddish brown, inner side is reddish brown and smooth. The folded surface is reddish brown with a thin layer of light brown and slightly fibrous.
황기(Astragali Radix)는 콩과(Leguminosae)에 속하는 황기(Astragalus membranaceus) 또는 그밖의 동속 근연식물의 뿌리 부위를 지칭하며, 주피를 벗겨 사용할 때가 많다. 황기는 가늘고 긴 원주형을 이루고 길이 30 cm 내지 100 cm, 지름 7 mm 내지 20 mm 이며, 드문드문 작은 가지뿌리가 붙어있으나 분지되는 일은 없고 근두부 가까이에서는 약간 꼬여지고 줄기의 잔기가 남아있다. 바깥면은 엷은 회황색-엷은 황갈색이며 회갈색의 코르크층이 군데군데 남아 있고 불규칙한 거친 세로의 주룸과 가로로 피목같은 모양이 보인다. 질은 치밀하고 꺾기 힘들며 꺾은 면은 섬유성이다.Astragali Radix refers to the root part of Astragalus membranaceus or other related plants belonging to Leguminosae, and it is often used peeled off. Hwanggi is a thin and long cylindrical shape with a length of 30 cm to 100 cm and a diameter of 7 to 20 mm. It has a sparse root, but it is not branched. It is slightly twisted near the head and remains a stem. The outer surface is pale yellowish-brownish, with a grayish brown cork layer in place, with irregularly coarse-grained vertical chambers and horizontal pine-like shapes. The quality is dense and hard to break, and the folded side is fibrous.
본 발명의 목적은 탈모의 예방 또는 치료용 약제학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing or treating hair loss.
본 발명의 다른 목적은 탈모의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or ameliorating hair loss.
본 발명의 또 다른 목적은 발모 촉진용 조성물을 제공하는 것이다.It is still another object of the present invention to provide a composition for promoting hair growth.
상기 목적을 달성하기 위하여, 본 발명자들은 기존의 탈모 치료제 및 발모제를 대체할 수 있는 새로운 물질에 관하여 연구를 계속하던 중, 육계 추출물 및 황기 추출물을 함유하는 복합 추출물이 탈모를 치료하고, 발모를 촉진할 수 있음을 확인하고 본 발명을 완성하였다.In order to achieve the above object, the inventors of the present invention have continued research on a novel substance that can replace the existing hair loss therapeutic agent and hair growth agent, and have found that a complex extract containing broiler and herbal extracts treat hair loss, And completed the present invention.
본 발명은 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 탈모의 예방 또는 치료용 약제학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating hair loss comprising broiler chick extract and Hwanggi extract as an active ingredient.
본 발명에서, 육계(Cinnamomi Cortex)는 Cinnamomum cassia 또는 그밖의 동속 근연식물의 줄기껍질을 의미한다. 상기 Cinnamomum cassia 또는 그밖의 동속 근연식물은 구체적으로, Cinnamomum cassia, Cinnamomum loureiroi, Cinnamomum verum, Cinnamomum burmannii, Cinnamomum wilsonii, Cinnamomum chingii, Cinnamomum japonicum, Cinnamomum zeylanicum, Cinnamomum obtusifolim 및 Cinnamomum sieboldii을 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 육계는 Cinnamomum verum의 줄기껍질일 수 있다.In the present invention, broiler (Cinnamomi Cortex) refers to the stem skin of Cinnamomum cassia or other related plants. Specific examples of the Cinnamomum cassia or other related plants include Cinnamomum cassia , Cinnamomum loureiroi , Cinnamomum verum , Cinnamomum burmannii , Cinnamomum wilsonii , Cinnamomum chingii , Cinnamomum japonicum , Cinnamomum zeylanicum , Cinnamomum obtusifolim and Cinnamomum sieboldii . It is not. In a specific embodiment of the invention, the broiler can be the stem shell of Cinnamomum verum .
본 발명에서, 황기(Astragali Radix)는 Astragalus membranaceus 또는 그밖의 동속 근연식물의 뿌리를 의미한다. 상기 Astragalus membranaceus 또는 그밖의 동속 근연식물은 구체적으로, Astragalus mongholicus, Astragalus uliginosus 및 Astragalus membranaceus var. mongholicus를 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 황기는 Astragalus membranaceus의 뿌리일 수 있다.In the present invention, Astragali Radix refers to the root of Astragalus membranaceus or other closely related plants. The above-mentioned Astragalus membranaceus or other related plants are, specifically, Astragalus mongholicus , Astragalus uliginosus and Astragalus membranaceus var. mongholicus , but are not limited thereto. In a specific embodiment of the invention, the Emperor can be the root of Astragalus membranaceus .
본 발명에서, 육계 및 황기는 자연 상태 그대로인 것뿐만 아니라, 반건조, 건조 등의 가공된 것을 포함한다.In the present invention, broiler chickens and horseshoe chickens are not only natural but also semi-dried and dried.
본 발명에서, 추출물(extract)은 천연물을 추출 처리하여 얻어지는 추출액, 상기 추출액의 분획물, 상기 추출액 또는 분획물의 조정제물이나 정제물, 또는 이들의 희석액, 농축액, 건조물, 또는 이들의 혼합물 등, 육계 및 황기로부터 형성가능한 모든 제형의 추출물을 포함한다.In the present invention, the extract may be an extract obtained by extracting a natural product, a fraction of the extract, a preparation or a purified product of the extract or the fraction, or a diluent, a concentrate, a dried product thereof or a mixture thereof, Lt; RTI ID = 0.0 > of all formulations < / RTI >
본 발명에서 추출물은 이 분야에 공지된 일반적 제조방법을 사용하여 제조될 수 있으며, 특별히 제한되지 않는다. 예를 들어, 초음파 추출법(sonication extraction), 초임계 추출법(supercritical extraction), 감압 추출법(vacumn extraction), 환류 추출법(reflux extraction), 열수 추출법(hot-water extraction), 고온 가압 추출법(autoclave extraction), 초고압 추출법(high-pressure extraction), 효소 추출법(enzyme extraction), 또는 추출 용매를 사용하여 공지의 방법에 의해 제조하는 방법일 수 있으나, 이에 한정되는 것은 아니다.The extract in the present invention can be produced using a general production method well known in the art, and is not particularly limited. For example, sonication extraction, supercritical extraction, vacumn extraction, reflux extraction, hot-water extraction, autoclave extraction, But not limited thereto, by a known method using a high-pressure extraction method, an enzyme extraction method, or an extraction solvent.
본 발명에서, 추출물은 물, 유기용매 또는 이들의 혼합물을 추출 용매로 하여 추출액으로 제조될 수 있다. 상기 물은 예를 들어, 증류수, 정제수, 무균수를 들 수 있으나, 이에 한정되는 것은 아니다. 상기 유기용매는 예를 들어, 알코올, 글리세린, 부틸렌글리콜, 프로필렌글리콜, 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르 및 디클로로메탄를 들 수 있으나, 이에 한정되는 것은 아니다. In the present invention, the extract can be prepared as an extract using water, an organic solvent or a mixture thereof as an extraction solvent. The water may be, for example, distilled water, purified water, or sterile water, but is not limited thereto. Examples of the organic solvent include, but are not limited to, alcohols, glycerin, butylene glycol, propylene glycol, methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether and dichloromethane.
본 발명에서, 추출물은 바람직하게는 물, 탄소수 1 내지 4의 저가 알코올(메탄올, 에탄올, 프로판올 또는 부탄올) 또는 이들의 혼합물로 이루어진 군에서 선택된 용매를 추출 용매로 하여 추출된 것일 수 있다. 상기 탄소수 1 내지 4의 저가 알코올의 농도는 10 % 내지 90 %일 수 있고, 바람직하게는 20 % 내지 70 % 일 수 있고, 더 바람직하게는 25 % 내지 50 % 일 수 있다. 본 발명의 구체적인 구현예에서, 육계 추출물은 증류수를 추출 용매로 하여 추출된 것일 수 있다. 본 발명의 구체적인 구현예에서, 황기 추출물은 증류수를 추출 용매로 하여 추출된 것일 수 있다.In the present invention, the extract may preferably be extracted with a solvent selected from the group consisting of water, lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol or butanol), or a mixture thereof, as an extraction solvent. The concentration of the lower alcohol having 1 to 4 carbon atoms may be 10% to 90%, preferably 20% to 70%, and more preferably 25% to 50%. In a specific embodiment of the present invention, the broiler chick extract may be extracted with distilled water as an extraction solvent. In a specific embodiment of the present invention, the Hwanggi extract may be extracted with distilled water as an extraction solvent.
본 발명에서, 분획물은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 수득된 결과물을 의미한다. 본 발명에서, 분획물은 추출액을 분획하여 제조될 수 있다.In the present invention, a fraction means an obtained product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various various constituents. In the present invention, the fraction may be prepared by fractionating the extract.
본 발명에서, 상기 분획물의 제조에 사용되는 분획 용매의 종류는 특별히 제한되지 않으며, 본 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매는 예를 들어, 물, 탄소수 1 내지 4의 알코올, 헥산, 에틸 아세테이트, 클로로포름, 디클로로메탄 또는 이들의 혼합물 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 분획 용매는 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있으며, 용매의 극성에 따라 순차적으로 사용하여 각 용매의 분획물을 제조할 수 있다.In the present invention, the kind of the fraction solvent used for preparing the fraction is not particularly limited, and any solvent known in the art can be used. Examples of the fraction solvent include, but are not limited to, water, an alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform, dichloromethane or a mixture thereof. The fraction solvents may be used alone or in combination of two or more kinds. The fractions of each solvent may be sequentially used according to the polarity of the solvent.
본 발명에서, 정제물은 추출액 또는 분획물에 추가의 정제 과정을 더 수행하여 수득된 결과물을 의미한다. 상기 정제는 이 분야에 공지된 일반적인 방법을 사용할 수 있으며, 예를 들어, 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 들 수 있으나, 이에 한정되는 것은 아니다.In the present invention, purified water refers to the result obtained by further performing an additional purification process on the extract or fraction. The tablets may be purified by conventional methods known in the art, for example, silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, But are not limited to, various chromatographic techniques.
본 발명에서, 추출물은 여과, 농축 또는 건조과정을 수행하여 용매가 제거되거나, 여과, 농축 및 건조를 모두 수행한 것일 수 있다. 상기 여과는 예를 들어, 여과지 또는 감압여과기를 이용할 수 있다. 상기 농축은 예를 들어, 감압 농축기 또는 회전 증발기를 이용할 수 있다. 상기 건조는 예를 들어, 분무건조법 또는 동결건조법으로 수행할 수 있다. In the present invention, the extract may be subjected to filtration, concentration or drying to remove the solvent, or to carry out both filtration, concentration and drying. The filtration may be performed using, for example, a filter paper or a vacuum filter. The concentration may be performed, for example, using a reduced pressure concentrator or a rotary evaporator. The drying may be carried out, for example, by spray drying or freeze-drying.
또한, 본 발명에서, 추출물은 사용 시까지 급속 냉동 냉장고(deep freezer)에 보관할 수 있고, 농축 및 동결건조를 통하여 수분을 완전히 제거시킬 수 있으며, 수분을 완전히 제거시킨 추출물은 분말형태로 사용하거나 상기 분말을 증류수 또는 통상의 용매에 녹여 사용할 수 있다.In addition, in the present invention, the extract can be stored in a deep freezer until use, and the water can be completely removed through concentration and freeze-drying, and the extract in which moisture is completely removed can be used in the form of powder, The powder may be dissolved in distilled water or a conventional solvent.
본 발명에서, 육계 추출물 및 황기 추출물은 육계와 황기를 각각 별도로 추출한 후 혼합한 것, 또는 육계와 황기를 추출 전 혼합하여 추출한 것을 모두 포함한다. 본 발명의 구체적인 구현예에서, 육계 추출물 및 황기 추출물은 육계와 황기를 각각 별도로 추출한 후 혼합한 것일 수 있다. In the present invention, the broiler chick extract and the hwanggi extract include those obtained by separately extracting broiler chickens and hwanggi, respectively, or those obtained by mixing broccoli and hwanggi before extraction. In a specific embodiment of the present invention, the broiler chick extract and the hwanggi extract may be obtained by separately extracting broiler chickens and hulls, respectively.
본 발명에서, "육계 및 황기 복합 추출물"은 육계와 황기를 각각 별도로 추출한 후 혼합한 것, 또는 육계와 황기를 추출 전 혼합하여 추출한 것을 지칭하는 용어로 사용된다.In the present invention, the term " broiler chrysanthemum and its combination extracts "is used to refer to a mixture of broth and hwanggi separately, or a mixture of broccoli and hwanggi before extraction.
본 발명의 약제학적 조성물에서, 육계 추출물 및 황기 추출물의 함량비는 1 : 0.5 내지 1 : 100, 바람직하게는 1 : 1 내지 1 : 10 일 수 있다. 본 발명의 구체적인 구현예에서, 육계 추출물 및 황기 추출물의 함량비는 1 : 4 일 수 있다. In the pharmaceutical composition of the present invention, the content ratio of the broiler chick extract and the Hwanggi extract may be 1: 0.5 to 1: 100, preferably 1: 1 to 1:10. In a specific embodiment of the present invention, the content ratio of broiler chick extract and hull extract can be 1: 4.
본 발명에서, 탈모는 피부로부터 모발이 탈락하는 현상 또는 모발이 성기거나 가늘어지는 상태를 의미하며, 탈모증과 혼용되어 사용될 수 있는 용어이다. In the present invention, hair loss refers to a state in which hair falls off from the skin or a state where the hair becomes thin or tapered, and can be used in combination with alopecia.
본 발명에서, 모발은 머리의 모근 및 모낭, 머리카락 및 속눈썹과 겉눈썹, 수염, 겨드랑이, 음모, 신체 전반에 모근 및 모낭이 있는 모든 부위를 포함한다.In the present invention, hair includes hair follicles and hair follicles, hair and eyelashes and eyelashes, whiskers, armpits, pubic hair, hair follicles and hair follicles.
본 발명에서, 탈모는 구체적으로 안드로겐성 탈모, 휴지기 탈모, 약제성 탈모, 기계적 탈모, 외상성 탈모, 압박성 탈모, 생장기 탈모, 비강성 탈모, 매독성 탈모, 지루 탈모, 증후성 탈모, 반흔성 탈모, 선천성 탈모, 원형 탈모, 머리 백선, 전두 탈모, 감모증, 유전성 단순 감모증 및 전신 탈모로 이루어진 군에서 선택되는 하나 이상일 수 있다. 그러나 탈모는 발생의 직간접적인 원인을 불문하고 이 분야에서 탈모로 분류되는 모든 증상을 포함하는 의미로서 이해되어야 한다.In the present invention, hair loss is concretely exemplified by androgenetic hair loss, resting hair loss, pharmaceutical hair loss, mechanical hair loss, traumatic hair loss, compressive hair loss, growth hair loss hair loss, non-rigid hair loss, , Congenital hair loss, round hair loss, hair ringworm, frontal hair loss, gingham disease, hereditary simple gait and general hair loss. However, hair loss should be understood to include all symptoms classified as hair loss in this field, whether directly or indirectly related to the occurrence.
본 발명의 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 모발이 제거된 상태에서 모발의 생성 및 성장을 촉진한다. 또한, 본 발명의 육계 추출물 및 황기 추출물을 포함하는 조성물은 5α-리덕타아제의 발현을 억제할 수 있다. 따라서 본 발명의 약제학적 조성물은 탈모의 예방 또는 치료용으로 효과적으로 사용될 수 있다.According to a specific embodiment of the present invention, a composition comprising a broiler chick extract and a Hwanggi extract promotes the production and growth of hair in the state of removing the hair. In addition, the composition comprising the broiler chick extract and the Hwanggi extract of the present invention can inhibit the expression of 5α-reductase. Therefore, the pharmaceutical composition of the present invention can be effectively used for preventing or treating hair loss.
본 발명에서, "유효성분"은 단독으로 목적하는 활성을 나타내거나, 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In the present invention, the term "active ingredient" alone means an ingredient which exhibits the desired activity or which can exhibit activity together with a carrier which is itself inactive.
본 발명에서, "예방"은 본 발명의 약제학적 조성물의 투여에 의해 탈모와 연관된 하나 이상의 증상의 발생 또는 발병이 억제되거나 지연되는 모든 행위를 의미하며, 반드시 탈모의 완전한 발병 억제를 의미하는 것은 아니다. In the present invention, "prevention" means any action in which the occurrence or development of one or more symptoms associated with hair loss is inhibited or delayed by the administration of the pharmaceutical composition of the present invention, and does not necessarily mean complete inhibition of hair loss .
본 발명에서, "치료"는 본 발명의 약제학적 조성물의 투여에 의해 탈모와 연관된 하나 이상의 증상을 나타내고 있거나, 이전에 나타냈던 개체의 증상이 억제되거나, 감소되거나 또는 호전되는 모든 행위를 의미한다. 상기 개체는 인간을 포함하는 포유류일 수 있으며, 바람직하게는 인간이다.In the present invention, "treatment" means any action that indicates one or more symptoms associated with hair loss by administration of the pharmaceutical composition of the present invention, or that inhibits, decreases or improves the symptoms of a previously described individual. The subject can be a mammal, including a human, and is preferably a human.
본 발명에서, "투여"는 어떠한 적절한 방법으로 개체에 본 발명의 약제학적 조성물을 도입하는 것을 의미한다. 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명의 약제학적 조성물이 표적 세포로 이동할 수 있도록 하는 임의의 장치에 의해 투여될 수 있다.In the present invention, "administration" means introducing the pharmaceutical composition of the present invention into a subject by any appropriate method. The route of administration may be oral or parenteral administration via any conventional route so long as it can reach the target tissue. In addition, the pharmaceutical composition of the present invention can be administered by any device that allows it to migrate to a target cell.
본 발명의 약제학적 조성물은 본 발명의 효과를 해치지 않는 범위에서 약제학적으로 허용되는 담체를 추가로 포함할 수 있다. 본 발명에서 사용될 수 있는 약제학적으로 허용되는 담체의 종류는 특별히 제한되지 아니하며, 이 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체는 예를 들어, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 말토 덱스트린, 글리세롤, 에탄올 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 담체는 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier to the extent that the effect of the present invention is not impaired. The type of the pharmaceutically acceptable carrier to be used in the present invention is not particularly limited, and any carrier commonly used in this technical field can be used. The carrier may include, for example, saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, , But is not limited thereto. The carrier may be used alone or in combination of two or more.
본 발명의 약제학적 조성물은 본 발명의 효과를 해치지 않는 범위에서 약제학적으로 허용되는 첨가제를 추가로 포함할 수 있다. 본 발명에서 사용될 수 있는 약제학적으로 허용되는 첨가제의 종류는 특별히 제한되지 아니하며 이 기술 분야에서 통상적으로 사용되는 첨가제라면 어느 것이든 사용할 수 있다. 상기 첨가제는 예를 들어, 충전제, 결합제, 붕해제, 윤활제, 현탁화제, 용제, 산화방지제, pH 조절제, 습윤제, 감미제 및 보존제를 들 수 있으나, 이에 한정되지는 것은 아니다. 상기 첨가제는 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive to the extent that the effect of the present invention is not impaired. The kind of the pharmaceutically acceptable additive which can be used in the present invention is not particularly limited and any additive conventionally used in this technical field can be used. Such additives include, but are not limited to, for example, fillers, binders, disintegrants, lubricants, suspending agents, solvents, antioxidants, pH adjusting agents, humectants, sweeteners and preservatives. These additives may be used alone or in combination of two or more.
본 발명의 약제학적 조성물은 경구 투여 또는 비경구 투여를 위한 적합하고 다양한 제형이 될 수 있다. 본 발명에서, 경구 투여용 제형은 예를 들어, 정제, 환제, 분말, 산제, 과립, 펠렛, 캡슐, 트로키(troches), 로젠지(lozenge), 현탁액, 에멀젼, 시럽 및 엘릭시르제 등을 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명에서, 비경구 투여용 제형은 예를 들어, 주사제, 좌제, 호흡기 흡입제, 에어로졸제, 연고, 도포용 분말, 오일, 크림, 겔 및 샴푸 등을 들 수 있으나, 이에 한정되는 것은 아니다.The pharmaceutical compositions of the present invention may be suitable and various formulations for oral or parenteral administration. In the present invention, formulations for oral administration include, for example, tablets, pills, powders, powders, granules, pellets, capsules, troches, lozenges, suspensions, emulsions, syrups and elixirs But is not limited thereto. In the present invention, formulations for parenteral administration include, but are not limited to, injections, suppositories, respiratory inhalants, aerosols, ointments, application powders, oils, creams, gels and shampoos.
본 발명의 약제학적 조성물은 목적에 따라 경구 투여하거나 비경구 투여할 수 있다. 본 발명에서, 비경구 투여는 예를 들어, 복강 투여, 직장 투여, 피하 투여, 정맥 투여, 근육 투여, 흉부 투여, 경피 투여 및 모발 투여를 들 수 있고, 조성물을 질환 부위에 도포하거나 분무, 흡입하는 것도 들 수 있으나. 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 본 발명의 약제학적 조성물은 경구 투여될 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally depending on the purpose. In the present invention, parenteral administration includes, for example, intraperitoneal administration, rectal administration, subcutaneous administration, intravenous administration, muscle administration, chest administration, transdermal administration and hair administration, It can also be done. But is not limited thereto. In a specific embodiment of the invention, the pharmaceutical composition of the present invention can be administered orally.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에서, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효한 양의 수준은 환자의 상태, 체중, 성별, 연령, 건강상태, 질병의 정도, 약물에 대한 민감도, 투여 시간, 투여 경로, 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약제학적 조성물의 투여량은 통상의 기술자에 의해 적절하게 선택될 수 있다. 본 발명의 약제학적 조성물의 투여량은 육계 추출물 및 황기 추출물의 함량을 기준으로 1일 0.1 mg/kg 내지 2,000 mg/kg 일 수 있고, 보다 바람직하게는 1 mg/kg 내지 500 mg/kg 일 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 투여량의 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective amount level will vary depending on the condition of the patient, The severity of the disease, the sensitivity to the drug, the time of administration, the route of administration, the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The dosage of the pharmaceutical composition of the present invention can be suitably selected by a person skilled in the art. The dosage of the pharmaceutical composition of the present invention may be from 0.1 mg / kg to 2,000 mg / kg per day, more preferably from 1 mg / kg to 500 mg / kg per day based on the content of broiler chick extract and hwanggi extract But is not limited thereto. Further, the scope of the present invention is not limited to these dosages.
본 발명의 약제학적 조성물의 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있으며, 수일에 한 번 투여할 수도 있다. The pharmaceutical composition of the present invention may be administered once a day, divided into several times, or administered once every several days.
본 발명의 약제학적 조성물은 탈모의 예방 및 치료를 위하여 단독으로, 또는 다른 예방 또는 치료제와 병용하여 투여될 수 있고, 다른 예방 또는 치료제와 동시에 또는 순차적으로 투여될 수 있다. 또한, 본 발명의 약제학적 조성물은 수술, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용될 수 있다.The pharmaceutical composition of the present invention may be administered alone or in combination with other preventive or therapeutic agents for the prevention and treatment of hair loss, and may be administered simultaneously or sequentially with other preventive or therapeutic agents. In addition, the pharmaceutical composition of the present invention can be used in combination with methods using surgery, hormone therapy, chemotherapy, and biological response modifiers.
본 발명은 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 탈모의 예방 또는 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing or ameliorating hair loss comprising broiler chick extract and Hwanggi extract as an active ingredient.
본 발명의 식품 조성물에서, 육계, 황기, 추출물, 유효성분 및 탈모는 앞서 본 발명의 약제학적 조성물에 대해 상세하게 기재한 바와 동일하다.In the food composition of the present invention, the broiler chick, the yellow brood, the extract, the active ingredient and the hair loss are the same as those described above in detail for the pharmaceutical composition of the present invention.
본 발명의 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 모발이 제거된 상태에서 모발의 생성 및 성장을 촉진한다. 따라서 본 발명의 식품 조성물은 탈모의 예방 또는 개선용으로 효과적으로 사용될 수 있다.According to a specific embodiment of the present invention, a composition comprising a broiler chick extract and a Hwanggi extract promotes the production and growth of hair in the state of removing the hair. Therefore, the food composition of the present invention can be effectively used for prevention or improvement of hair loss.
본 발명에서, "예방"은 본 발명의 식품 조성물의 섭취에 의해 탈모와 연관된 하나 이상의 증상의 발생 또는 발병이 억제되거나 지연되는 모든 행위를 의미하며, 반드시 탈모의 완전한 발병 억제를 의미하는 것은 아니다. In the present invention, "prevention" means any action in which the onset or onset of one or more symptoms associated with hair loss is inhibited or delayed by ingestion of the food composition of the present invention, and does not necessarily mean complete inhibition of hair loss.
본 발명에서, "개선"은 본 발명의 식품 조성물의 섭취에 의해 탈모와 연관된 하나 이상의 증상의 정도가 감소되거나 호전되거나 진행이 지연되는 모든 행위를 의미한다.In the present invention, "improvement" means any action whereby the degree of one or more symptoms associated with hair loss by the ingestion of the food composition of the present invention is reduced, improved or delayed.
본 발명의 식품 조성물은 육계 추출물 및 황기 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. The food composition of the present invention can be used as it is or directly with other food or food ingredients, and can be suitably used according to conventional methods.
본 발명의 식품 조성물은 육계 추출물 및 황기 추출물을 유효성분으로 포함하며, 유효성분의 함량은 사용 목적에 따라 적합하게 결정될 수 있다. 일반적으로, 육계 추출물 및 황기 추출물은 식품 조성물의 총중량에 대하여 0.0001 내지 100 중량%로 첨가될 수 있다.The food composition of the present invention contains a broiler chick extract and an extract of Hwanggi as an active ingredient, and the content of the active ingredient may be suitably determined according to the purpose of use. In general, the broiler chick extract and the hull extract can be added in an amount of 0.0001 to 100% by weight based on the total weight of the food composition.
본 발명에서, 식품 조성물의 형태에는 특별한 제한이 없으며, 통상적인 의미에서의 식품을 모두 포함한다. 본 발명이 적용될 수 있는 식품으로는, 예를 들어, 음료, 드링크제, 건강기능식품 등이 있다.In the present invention, the form of the food composition is not particularly limited, and includes foods in a conventional sense. Foods to which the present invention can be applied include, for example, beverages, drinks, and health functional foods.
본 발명에서, "건강기능식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 제조 및 가공한 식품을 의미한다. 상기 건강기능식품은 경우에 따라, 기능성식품, 건강식품 또는 건강보조식품 등의 용어와 호용된다. 또한, 본 발명에서, "기능"이란 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적인 작용으로 보건 용도에 유용한 효과를 의미할 수 있다.In the present invention, the term "health functional food" refers to a food prepared and processed so that the organism control function appears efficiently in addition to the nutritional supply by using raw materials and components having useful functions in the human body. The health functional foods are sometimes used in combination with terms such as functional foods, health foods, and health supplements. Further, in the present invention, "function" may mean an effect useful for health use by regulating nutrients or physiological actions on the structure and function of the human body.
본 발명의 식품 조성물은 통상적으로 식품의 냄새, 맛 또는 시각 등을 향상시킬 수 있는 식품 첨가제를 추가로 더 포함할 수 있다. 상기 식품 첨가제는 예를 들어, 풍미제, 증진제, 탄산화제 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 디히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸, 부틸히드록시톨루엔등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제 및 개량제를 들 수 있으나, 이에 한정되는 것은 아니다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The food composition of the present invention may further include a food additive which can usually improve the odor, taste or visual appearance of the food. Such food additives include, for example, flavorings, enhancers, carbonating agent preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroxyacetate), disinfectants (such as bleaching powder and highly bleached white powder, sodium hypochlorite), antioxidants (Sodium nitrite), bleach (sodium sulfite), seasoning (such as sodium MSG glutamate), sweeteners (such as sodium cyanate, sodium cyanate and the like), coloring agents (Antioxidant), antioxidant, antiseptic agent, antiseptic agent, antiseptic agent, antiseptic agent, antiseptic agent, antiseptic agent, antiseptic agent, But is not limited thereto. The additives may be selected and used in appropriate amounts depending on the type of food.
본 발명의 식품 조성물은 식품의 기능성을 향상시킬 수 있는 추가의 성분을 더 포함할 수 있다. 예들 들어, 비타민(vitamin), 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. The food composition of the present invention may further comprise additional components capable of improving the functionality of the food. For example, it may include vitamins, niacin, biotin, folate, panthotenic acid, and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like.
본 발명의 식품 조성물은 식품 첨가물로 사용할 수 있으며, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The food composition of the present invention can be used as a food additive, and can be added as it is or can be used together with other food or food ingredients, and can be suitably used according to a conventional method.
본 발명의 식품 조성물이 음료 또는 드링크제인 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 향미제는 예를 들어, 사카린, 아스파르탐 등을 들 수 있다. 상기 천연 탄수화물은 예를 들어, 모노사카라이드(포도당, 과당 등), 디사카라이드(말토스, 수크로스 등), 및 폴리사카라이드(덱스트린, 시클로덱스트린 등)와 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리스리톨 등의 당알코올을 들 수 있다. 그 밖에 본 발명의 식품 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다.When the food composition of the present invention is a beverage or a drink, it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the flavoring agent include saccharin, aspartame, and the like. Such natural carbohydrates include, for example, conventional sugars such as monosaccharides (glucose, fructose, etc.), disaccharides (maltose, sucrose etc.) and polysaccharides (dextrin, cyclodextrin and the like) And sugar alcohols such as sorbitol and erythritol. In addition, the food composition of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination.
본 발명은 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 발모 촉진용 조성물을 제공한다.The present invention provides a composition for promoting hair growth comprising a broiler chick extract and a hwanggi extract as an effective ingredient.
본 발명의 발모 촉진용 조성물에서, 육계, 황기, 추출물 및 유효성분 은 앞서 본 발명의 약제학적 및 식품 조성물에 대해 상세하게 기재한 바와 동일하다.In the composition for promoting hair growth of the present invention, the broiler chick, the yellow brood, the extract, and the active ingredient are the same as those described above in detail for the pharmaceutical and food composition of the present invention.
본 발명에서, "발모"는 모발의 생성 및 성장을 의미하며, 이 분야에서 사용되는 용어 양모 또는 육모의 의미를 포함하는 광의의 개념이다.In the present invention, "hair growth" refers to the generation and growth of hair, and is a broad concept including the meaning of the term wool or hair growth as used in this field.
본 발명의 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 모발이 제거된 상태에서 모발의 생성 및 성장을 촉진한다. 따라서 본 발명의 조성물은 발모 촉진용으로 효과적으로 사용될 수 있다.According to a specific embodiment of the present invention, a composition comprising a broiler chick extract and a Hwanggi extract promotes the production and growth of hair in the state of removing the hair. Therefore, the composition of the present invention can be effectively used for promoting hair growth.
본 발명의 발모 촉진용 조성물은 화장료 조성물로 사용될 수 있다. 상기 화장료 조성물은 예를 들어, 용액, 솔젤, 현탁액, 에멀젼, 페이스트, 마이크로캡슐, 오일, 왁스, 에어졸의 형태로 제형화 될 수 있으나, 이에 한정되는 것은 아니다. 상기 화장료 조성물의 구체적인 제형은 예를 들어, 헤어토닉, 헤어크림, 헤어팩, 헤어로션, 헤어샴푸, 헤어린스, 헤어비누, 헤어컨디셔너, 헤어스프레이, 헤어에어졸, 헤어 왁스, 헤어젤, 포마드 및 분말 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 화장료 조성물은 화장료 조성물에 통상적으로 사용되는 보조제를 추가로 더 포함할 수 있다. 상기 보조제는 예를 들어, 겔화제, 활성제, 보존제, 항산화제, 용매, 방향제, 충전제, 차단제, 안료, 흡취제 및 염료 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 화장료 조성물은 모발 또는 두피에 직접 도포 또는 산포하는 등의 방법에 의해 사용될 수 있다.The hair growth stimulating composition of the present invention can be used as a cosmetic composition. The cosmetic composition may be, for example, in the form of a solution, a solsgel, a suspension, an emulsion, a paste, a microcapsule, an oil, a wax and an aerosol. Specific formulations of the cosmetic composition include, for example, hair tonics, hair creams, hair packs, hair lotions, hair shampoos, hair rinses, hair soaps, hair conditioners, hair sprays, hair aerosols, hair waxes, hair gels, But the present invention is not limited thereto. The cosmetic composition may further comprise auxiliary agents conventionally used in cosmetic compositions. Examples of the adjuvant include, but are not limited to, a gelling agent, an activator, a preservative, an antioxidant, a solvent, a perfume, a filler, a barrier agent, a pigment, a hygroscopic agent and a dye. The above-mentioned cosmetic composition can be used by directly applying or dispersing the hair or scalp.
본 발명의 발모 촉진용 조성물은 목적에 따라 경구 투여하거나 비경구 투여할 수 있다. 본 발명에서, 비경구 투여는 예를 들어, 복강 투여, 직장 투여, 피하 투여, 정맥 투여, 근육 투여, 흉부 투여, 경피 투여를 들 수 있고, 조성물을 두피 또는 모발에 도포하거나 분무, 흡입하는 것도 들 수 있으나. 이에 한정되는 것은 아니다. The composition for promoting hair growth of the present invention may be administered orally or parenterally depending on the purpose. In the present invention, parenteral administration includes, for example, intraperitoneal administration, rectal administration, subcutaneous administration, intravenous administration, muscle administration, thoracic administration and transdermal administration, and the application of the composition to the scalp or hair, You can. But is not limited thereto.
본 발명의 발모 촉진용 조성물은 모발성장 촉진 보조성분을 추가로 포함할 수 있다. 모발성장 촉진 보조성분은 5알파-환원효소 억제 성분, 모근 및 모낭세포 활성 성분, 모낭세포 혈류 증강 성분, 살균 성분, 비듬방지제, 각질 연화제, 청량제, 보습제 등을 포함하나, 이에 한정되는 것은 아니다.The hair growth stimulating composition of the present invention may further comprise a hair growth promoting auxiliary component. Hair growth promoting auxiliaries include, but are not limited to, 5 alpha-reducing enzyme inhibitors, hair follicle and hair follicle cell active ingredients, hair follicle cell flow enhancing ingredients, bactericidal ingredients, antidandruff agents, exfoliants, coolants and moisturizers.
육계 추출물 및 황기 추출물을 포함하는 조성물은 모발이 제거된 상태에서 모발의 생성 및 성장을 촉진한다. 또한, 본 발명의 육계 추출물 및 황기 추출물을 포함하는 조성물은 5α-리덕타아제의 발현을 억제할 수 있다. 따라서 본 발명의 식품 조성물은 탈모의 예방, 치료 또는 개선용, 및 발모 촉진용으로 효과적으로 사용될 수 있다.A composition comprising a broiler chick extract and a Hwanggi extract promotes the production and growth of hair in the state of removing the hair. In addition, the composition comprising the broiler chick extract and the Hwanggi extract of the present invention can inhibit the expression of 5α-reductase. Therefore, the food composition of the present invention can be effectively used for prevention, treatment or amelioration of hair loss, and promotion of hair growth.
도 1은 실시예 1에서 정상대조군(NC), 음성대조군(AGA) 및 실험군(Sample group)의 피부를 관찰한 사진이다.
도 2는 실시예 1에서 정상대조군(NC), 음성대조군(AGA) 및 실험군(Sample group)의 피부를 더모스코프로 관찰한 사진이다.
도 3은 실시예 2에서 정상대조군(NC), 음성대조군(AGA) 및 실험군(Sample group)의 조직을 염색하여 광학 현미경으로 관찰한 것을 나타낸 것이다.
도 4는 실시예 3에서 정상대조군(NC), 음성대조군(AGA) 및 실험군(Sample group)의 카스파아제-8(caspase-8) 발현 정도를 웨스턴 블롯으로 확인한 결과를 나타낸 사진 및 그래프이다.
도 5는 실시예 3에서 정상대조군(NC), 음성대조군(AGA) 및 실험군(Sample group)의 카스파아제-9(caspase-9) 발현 정도를 웨스턴 블롯으로 확인한 결과를 나타낸 사진 및 그래프이다.
도 6은 실시예 3에서 정상대조군(NC), 음성대조군(AGA) 및 실험군(Sample group)의 p53 발현 정도를 웨스턴 블롯으로 확인한 결과를 나타낸 사진 및 그래프이다.1 is a photograph of the skin of a normal control group (NC), a negative control group (AGA) and an experimental group (Sample group) in Example 1;
Fig. 2 is a photograph of the skin of the normal control group (NC), the negative control group (AGA) and the experimental group (Sample group) more prospectively in Example 1.
FIG. 3 shows the staining of tissues of a normal control (NC), a negative control (AGA) and a sample group in Example 2 and observation with an optical microscope.
FIG. 4 is a photograph and a graph showing the result of Western blotting the expression level of caspase-8 in the normal control group (NC), the negative control group (AGA) and the experimental group (sample group)
FIG. 5 is a photograph and a graph showing the results of Western blotting the expression level of caspase-9 in normal control (NC), negative control (AGA) and experimental group (sample group)
FIG. 6 is a photograph and a graph showing a result of Western blotting the p53 expression level of a normal control (NC), a negative control (AGA) and an experimental group (sample group) in Example 3.
이하에서, 본 발명을 구체적인 제조예 및 실시예를 통하여 보다 상세히 설명한다. 그러나 하기 실시예는 본 발명의 이해를 돕기 위하여 제공되는 것일 뿐, 실시예에 의하여 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to specific production examples and examples. However, the following examples are provided to aid understanding of the present invention, and the scope of the present invention is not limited by the examples.
<제조예><Production Example>
제조예 1: 육계 추출물의 제조Production Example 1: Preparation of broiler chick extract
육계(500 g)에 3차 증류수(3.75 L)를 가하여 100 ℃에서 2시간 열수 추출한 후 여과하였다. 여과액을 55 ± 2 ℃에서 회전 감압농축기(rotary vacuum evaporator, EYELA, Tokyo, Japan)로 감압 농축 후, 동결 건조하여 20.1 g 파우더 상태의 육계 열수 추출물(수율: 4%)을 수득하였다.Third broth (3.75 L) was added to the broiler (500 g), and the mixture was subjected to hot water extraction at 100 ° C for 2 hours, followed by filtration. The filtrate was concentrated under reduced pressure using a rotary vacuum evaporator (EYELA, Tokyo, Japan) at 55 ± 2 ° C and then lyophilized to obtain 20.1 g of a broth hot water extract (yield: 4%) in powder form.
제조예 2: 황기 추출물의 제조Production Example 2: Preparation of Hwanggi Extract
황기는 정도 생약국(Seoul, Korea)에서 건조된 뿌리 형태로 구입한 후 경희대학교 한의과대학 융합한의과학교실에서 형태학적 및 화학적으로 동정하여 사용하였다. 황기(150 g)에 증류수(1.5 L)을 가하여 100 ℃에서 2시간 열수 추출 한 후 여과하였다. 여과액을 55 ± 2 ℃에서 회전 감압농축기(rotary vacuum evaporator, EYELA, Tokyo, Japan)로 감압 농축 후, 동결 건조하여 24.3 g 파우더 상태의 황기 열수 추출물(수율: 16.2%)을 수득하였다.Hwanggi was purchased in the form of dried roots from the Department of Oriental Medicine (Seoul, Korea) and used morphologically and chemically in the science classrooms of Kyunghee University College of Oriental Medicine. Distilled water (1.5 L) was added to Hwanggi (150 g), and the mixture was subjected to hot water extraction at 100 ° C for 2 hours, followed by filtration. The filtrate was concentrated under reduced pressure using a rotary vacuum evaporator (EYELA, Tokyo, Japan) at 55 ± 2 ° C and then lyophilized to obtain 24.3 g of a crude watery hot water extract (yield: 16.2%) in powder form.
제조예 3: 육계 및 황기 복합 추출물의 제조Production Example 3: Preparation of broiler chrysanthemum and Hwanggi complex extract
제조예 1에서 수득한 육계 추출물 및 제조예 2에서 수득한 황기 추출물을 1 : 4 의 중량 비율로 혼합하여 육계 및 황기 복합 추출물을 수득하였다.The broiler chick extract obtained in Preparation Example 1 and the hwanggeuk extract obtained in Preparation Example 2 were mixed in a weight ratio of 1: 4 to obtain a broiler chick and Huanggei complex extract.
<실시예> 육계 및 황기 복합 추출물을 포함하는 조성물의 탈모 예방, 치료, 개선 효과, 및 발모 촉진 효과 확인<Examples> Confirmation of Hair Loss Prevention, Treatment, Improvement Effect, and Hair Growth Promoting Effect of Composition Comprising Broiler Chicks and Hwanggi Combined Extract
실험 동물Experimental animal
실시예 1 내지 3에서 실험동물은 체중 20 g 내외의 암컷 7주령의 C57BL/6J 정상 생쥐를 이용하였다. 모든 생쥐는 대한바이오링크(충북, 음성)로부터 구매하여 일주일 동안의 적응기를 통해 본 실험에 사용되었다. 전 실험 기간 동안 모든 생쥐들은 표준화된 고형사료와 물을 공급받았으며, 사육실의 온도는 23 ± 2°C, 습도 50 ± 10%, 광주기와 암주기(light-dark cycle)는 12시간-12시간으로 유지되었다. The experimental animals used in Examples 1 to 3 were C57BL / 6J normal mice at 7 weeks of age and weighing about 20 g. All mice were purchased from Korean BioLink (Chungbuk, Korea) and used for this experiment through a week of adaptation period. During the entire experiment period, all mice were fed standardized solid feed and water, and the temperature of the feeding chamber was 23 ± 2 ° C, humidity 50 ± 10%, light-dark cycle 12 to 12 hours Respectively.
실험 모델 유발 및 약물 처리Experimental model induction and drug treatment
각 군의 생쥐(n = 6)는 정상대조군(NC, normal control group), 등 부위의 털을 제모한 음성대조군(AGA, negative control group), 등 부위의 털을 제모하고 제조예 3의 복합 추출물을 처리한 실험군(sample group)으로 나뉘어졌다. 발모효과를 관찰하기 위하여 전기제모기(electric clipper)를 사용하여 실험 시작 후 마우스의 등 부위의 털을 제거한 후 제모제를 발라 완전한 제모를 하였다. 정상대조군과 음성대조군에는 비히클(증류수)을 처리하였으며, 제조예 3의 복합 추출물은 100 mg/kg의 양으로 처리하였으며, 증류수에 녹여 100 μL씩 구강투여 하였다. 매일 1회씩 총 14일간 반복하였으며, 15일 째 되는 날 실험 목적에 따라 생쥐를 희생하였다. 분석을 위하여 병변 부위의 피부 조직을 적출하였다. 적출된 피부 조직을 이하의 실시예 2 및 3에 사용하였다.The mice of each group (n = 6) were treated with normal control group (NC), a negative control group (AGA) (Sample group). In order to observe the hair growth effect, an electric clipper was used to remove hair from the back part of the mouse after the experiment, and hair removal was applied to complete hair removal. A vehicle (distilled water) was treated with a normal control and a negative control, and the compound extract of Preparation Example 3 was administered in an amount of 100 mg / kg, dissolved in distilled water, and administered orally in a volume of 100 μL. The mice were sacrificed on the 15th day according to the purpose of the experiment. The skin tissue of the lesion was excised for analysis. The extracted skin tissue was used in the following Examples 2 and 3.
통계처리Statistical processing
실시예 1 내지 3에서 실험 결과는 평균 ± 표준오차(mean ± S.E.M) 값으로 표시하였으며, 집단 간 평균치 차이는 각 실험 결과를 통하여 ANOVA (analysis of variance)를 구한 후 던칸 다중 범위 검정(Duncan's multiple range test)을 이용하여 p < 0.05 수준에서 검증하였다.The experimental results in Examples 1 to 3 were expressed as the mean ± standard deviation (mean ± SEM), and the mean value difference between the groups was obtained by ANOVA (analysis of variance) using Duncan's multiple range test) at p <0.05 level.
실시예 1: 육안 관찰Example 1: Visual observation
육계 및 황기 복합 추출물의 발모 효능을 관찰하기 위하여 실험 시작 15일 째 되는 날 생쥐를 희생하기 전 졸레틸과 럼푼이 1:1로 혼합된 마취제를 희석하여 복강 투여하였다. 마취된 생쥐의 등 부위를 카메라(Sony, Tokyo, Japan)와 더모스코프(dermoscope) (Smart Microscope Pro; Kangjin Technology, Ltd., Seoul, Korea)로 촬영한 후 정상대조군 및 음성대조군과 비교 관찰하였다. 카메라로 촬영한 결과를 도 1에 나타내었으며, 더모스코프로 촬영한 결과를 도 2에 나타내었다.On the 15th day after the start of the experiment, mice were sacrificed and injected intraperitoneally with diluted anesthetic mixed with 1: 1 mixture of Zoletil and rumun. The back region of the anesthetized mice was photographed with a camera (Sony, Tokyo, Japan) and a dermoscope (Smart Microscope Pro; Kangjin Technology, Ltd., Seoul, Korea) and compared with the normal control group and the negative control group. FIG. 1 shows the result of photographing with a camera, and FIG. 2 shows the result of further photographing with MOSCO.
도 1 및 2에 나타낸 바와 같이, 육계 및 황기 복합 추출물을 처리한 군에서 음성대조군 대비 모발의 성장이 월등히 우수한 것을 확인할 수 있다. 따라서, 본 발명의 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 조성물은 탈모의 예방, 치료, 개선, 및 발모 촉진용으로 효과적으로 사용될 수 있다.As shown in Figs. 1 and 2, it can be confirmed that the hair growth in the group treated with the broiler chrysanthemum and Huanggei complex extract was much better than that in the negative control group. Therefore, the composition comprising the broiler chick extract and the Hwanggi extract as an active ingredient of the present invention can be effectively used for prevention, treatment, improvement, and hair growth promotion of hair loss.
실시예 2: 조직학적 평가Example 2: Histological evaluation
적출한 등 피부 조직을 24시간 동안 4% 포르말린에 고정한 후, 조직의 탈수를 위해 순서대로 저농도의 70% 에탄올부터 80% 에탄올, 90% 에탄올, 95% 에탄올 및 고농도 100% 알코올까지 탈수하고, 자일렌에 투명과정을 거친 다음 파라핀 블록을 제작하였다. 제작된 블록은 4 μm 두께로 박절하여 탈파라핀 및 100% 에탄올에서 70% 에탄올을 거쳐 함수시켰다. 증류수에 수세시킨 조직 슬라이드를 헤마토실린(hematoxylin) & 에오신(eosin) (H&E)으로 각각 염색하여 퍼마운트(permount)로 봉입하였다. 염색된 조직은 광학현미경(Leica Microsystems Inc., IL, USA)에서 × 200 배율로 관찰하였으며, 그 결과를 도 3에 나타내었다.The skin tissues were fixed in 4% formalin for 24 hours and dehydrated in order of dehydration from low concentration 70% ethanol to 80% ethanol, 90% ethanol, 95% ethanol and high concentration 100% Paraffin blocks were produced after transparency to the rhenium. Blocks were cut to a thickness of 4 μm and deparaffinized and 100% ethanol were added to 70% ethanol. The tissue slides washed with distilled water were stained with hematoxylin and eosin (H & E), respectively, and sealed with a permount. The stained tissues were observed under an optical microscope (Leica Microsystems Inc., IL, USA) at a magnification of 200 ×, and the results are shown in FIG.
도 3에 나타낸 바와 같이, 육계 및 황기 복합 추출물을 처리한 군에서 음성대조군 대비 모낭의 형태가 안정되고, 모발의 형성이 촉진된 것을 확인할 수 있다. 따라서, 본 발명의 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 조성물은 탈모의 예방, 치료, 개선, 및 발모 촉진용으로 효과적으로 사용될 수 있다.As shown in FIG. 3, it was confirmed that the hair follicle morphology was stabilized and the hair formation was accelerated in the group treated with the broiler and hwanggi complex extracts as compared to the negative control group. Therefore, the composition comprising the broiler chick extract and the Hwanggi extract as an active ingredient of the present invention can be effectively used for prevention, treatment, improvement, and hair growth promotion of hair loss.
실시예 3: 탈모 관련 단백질 발현 억제 확인 (웨스턴 블롯)Example 3: Confirmation of inhibition of hair loss-related protein expression (Western blot)
적출된 피부 조직의 단백질을 추출하기 위하여 프로테아제 억제제 칵테일(protease inhibitors cocktail)이 포함된 단백질 추출 버퍼(protein extraction buffer) (50 mM Tris-HCl, 150 mM NaCl, 1% 트리톤 X-100, 1% 디옥시콜산 나트륨, 0.1% 도데실 황산 나트륨(SDS), 2 mM 에틸렌디아민테트라 아세트산(EDTA))를 넣어 분쇄하였다. 얻어진 단백질은 브래드포드(bradford) 법을 사용하여 정량하였다. 정량된 단백질 30 μg을 SDS 12% 폴리아크릴아미드 젤(polyacrylamide gel)에 전기영동하여 분리한 후 폴리비닐리덴 디플루오라이드(PVDF) 멤브레인으로 이동시켰다. 1차 항체를 반응시킨 후, 호스래디시 퍼옥시다아제(HRP) goat anti-rabbit을 처리하여 2차 반응을 유도시켰다. 발현된 단백질 밴드는 강화된 화학발광 분석 키트(enhanced chemiluminescence assay kit)를 이용하여 LAS 이미지 게이지(LAS Image Gauge) 프로그램에서 측정하였으며, 그 결과를 도 4 내지 6에 나타내었다.Protein extraction buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% di (2-ethylhexyl) acetate) containing a protease inhibitor cocktail Sodium oxycarboxylate, 0.1% sodium dodecyl sulfate (SDS), and 2 mM ethylenediaminetetraacetic acid (EDTA)) were added and pulverized. The obtained protein was quantified using the Bradford method. 30 μg of the quantified protein was separated by electrophoresis on a SDS 12% polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane. After the primary antibody was reacted, secondary reaction was induced by treatment with horseradish peroxidase (HRP) goat anti-rabbit. The expressed protein bands were measured in an LAS image gauge program using an enhanced chemiluminescence assay kit, and the results are shown in FIGS. 4 to 6. FIG.
도 4 내지 6에 나타낸 바와 같이, 음성 대조군의 경우 카스파아제-8(caspase-8), 카스파아제-9(caspase-9) 및 p53의 발현이 크게 증가하여 모발 퇴화기에 모낭 내 세포사멸이 일어났으나, 육계 및 황기 복합 추출물을 투여한 실험군의 경우 상기 단백질들의 발현 증가가 크게 완화되는 것으로 보아 육계 및 황기 복합 추출물이 모낭 내 항-세포사멸 효과를 가짐을 확인할 수 있다. 따라서, 본 발명의 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 조성물은 탈모의 예방, 치료, 개선, 및 발모 촉진용으로 효과적으로 사용될 수 있다.As shown in FIGS. 4 to 6, in the negative control group, expression of caspase-8, caspase-9, and p53 was significantly increased, resulting in intracellular apoptosis in the hair regrowth In the experimental group administered with the broth and broiler chick extract, the increase in the expression of the proteins was greatly alleviated, suggesting that the broiler chickens and Hwanggi complex extracts had an anti - apoptotic effect in the hair follicles. Therefore, the composition comprising the broiler chick extract and the Hwanggi extract as an active ingredient of the present invention can be effectively used for prevention, treatment, improvement, and hair growth promotion of hair loss.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 통상의 기술자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해되어야 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, it will be understood by those of ordinary skill in the art to which the present invention pertains that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described examples are illustrative in all aspects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180006439A KR102129409B1 (en) | 2018-01-18 | 2018-01-18 | Composition for treating hair loss and promoting hair growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180006439A KR102129409B1 (en) | 2018-01-18 | 2018-01-18 | Composition for treating hair loss and promoting hair growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190088207A true KR20190088207A (en) | 2019-07-26 |
| KR102129409B1 KR102129409B1 (en) | 2020-07-02 |
Family
ID=67469703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180006439A KR102129409B1 (en) | 2018-01-18 | 2018-01-18 | Composition for treating hair loss and promoting hair growth |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102129409B1 (en) |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3382247A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines |
| US5215894A (en) | 1992-02-25 | 1993-06-01 | Merck & Co., Inc. | Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors |
| JPH0873325A (en) * | 1994-09-06 | 1996-03-19 | Kao Corp | Hair-tonic and hair-growing agent |
| JPH10203933A (en) * | 1997-01-27 | 1998-08-04 | Kao Corp | Hair-restoring and growing agent |
| KR20010018668A (en) * | 1999-08-20 | 2001-03-15 | 유상옥 | A cosmetic composition containing Cinnamomi Cortex extracts |
| KR20040081716A (en) * | 2004-07-21 | 2004-09-22 | 김은선 | Composition comprising an extract of astragalusmembranaceus for hair growing promotor |
| KR100762413B1 (en) * | 2006-03-27 | 2007-10-04 | 한국미용화장품(주) | Compositon for prevention of hair loss and stimulation of hair growth |
| KR20080081393A (en) * | 2007-03-05 | 2008-09-10 | 주식회사 에이치비비지니스 | Hair growth promoting composition having extract of pogostemon cablin, sunflower, cinnamomum cassia blume |
| KR20100045817A (en) * | 2008-10-24 | 2010-05-04 | 호서대학교 산학협력단 | Soap with finely milled natural cinnamon powder and method for fabricating the same |
| KR20110125722A (en) * | 2010-05-14 | 2011-11-22 | 김수근 | Composition for moisturizing skin and composition for preventing hair loss or promoting hair generation having the extract of cinnamomum camphora sieb |
| KR20130059536A (en) * | 2011-11-29 | 2013-06-07 | (주)아모레퍼시픽 | Composition containing essential oil for relieving seborrheic dermatitis |
| KR20130090988A (en) * | 2012-02-07 | 2013-08-16 | 계명대학교 산학협력단 | Method for preparing supercritical fluid extract of cinnamomum verum and its use |
| KR101547758B1 (en) * | 2014-03-05 | 2015-08-26 | 주식회사 크라운진 | Composition for preventing hair loss and promoting hair growth |
| KR101797667B1 (en) | 2017-07-24 | 2017-12-12 | 최기남 | Composition for preventing, improving or treating hair loss and method for preparing the same |
| KR101810139B1 (en) | 2011-10-19 | 2017-12-19 | (주)아모레퍼시픽 | Composition for promoting hair growth and restoration |
| KR20190003269A (en) * | 2017-06-30 | 2019-01-09 | 남부대학교산학협력단 | Cpmposition for care of scalp disease comprinsing plant extract |
-
2018
- 2018-01-18 KR KR1020180006439A patent/KR102129409B1/en active IP Right Grant
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3382247A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines |
| US5215894A (en) | 1992-02-25 | 1993-06-01 | Merck & Co., Inc. | Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors |
| JPH0873325A (en) * | 1994-09-06 | 1996-03-19 | Kao Corp | Hair-tonic and hair-growing agent |
| JPH10203933A (en) * | 1997-01-27 | 1998-08-04 | Kao Corp | Hair-restoring and growing agent |
| KR20010018668A (en) * | 1999-08-20 | 2001-03-15 | 유상옥 | A cosmetic composition containing Cinnamomi Cortex extracts |
| KR20040081716A (en) * | 2004-07-21 | 2004-09-22 | 김은선 | Composition comprising an extract of astragalusmembranaceus for hair growing promotor |
| KR100762413B1 (en) * | 2006-03-27 | 2007-10-04 | 한국미용화장품(주) | Compositon for prevention of hair loss and stimulation of hair growth |
| KR20080081393A (en) * | 2007-03-05 | 2008-09-10 | 주식회사 에이치비비지니스 | Hair growth promoting composition having extract of pogostemon cablin, sunflower, cinnamomum cassia blume |
| KR20100045817A (en) * | 2008-10-24 | 2010-05-04 | 호서대학교 산학협력단 | Soap with finely milled natural cinnamon powder and method for fabricating the same |
| KR20110125722A (en) * | 2010-05-14 | 2011-11-22 | 김수근 | Composition for moisturizing skin and composition for preventing hair loss or promoting hair generation having the extract of cinnamomum camphora sieb |
| KR101810139B1 (en) | 2011-10-19 | 2017-12-19 | (주)아모레퍼시픽 | Composition for promoting hair growth and restoration |
| KR20130059536A (en) * | 2011-11-29 | 2013-06-07 | (주)아모레퍼시픽 | Composition containing essential oil for relieving seborrheic dermatitis |
| KR20130090988A (en) * | 2012-02-07 | 2013-08-16 | 계명대학교 산학협력단 | Method for preparing supercritical fluid extract of cinnamomum verum and its use |
| KR101547758B1 (en) * | 2014-03-05 | 2015-08-26 | 주식회사 크라운진 | Composition for preventing hair loss and promoting hair growth |
| KR20190003269A (en) * | 2017-06-30 | 2019-01-09 | 남부대학교산학협력단 | Cpmposition for care of scalp disease comprinsing plant extract |
| KR101797667B1 (en) | 2017-07-24 | 2017-12-12 | 최기남 | Composition for preventing, improving or treating hair loss and method for preparing the same |
Non-Patent Citations (2)
| Title |
|---|
| J. SOC. COSMET. SCIENTISTS KOREA, 2012 * |
| 네이버 블로그, 2011 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102129409B1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2703004B1 (en) | Composition for improving male sexual function containing ginseng berry extract | |
| KR101274868B1 (en) | Composition for Preventing Hair Loss and Improving Hair Condition Comprising an Extract of Asidian Tunic | |
| CA2924382A1 (en) | Lipid extract of passion fruit seeds | |
| JP2008525462A (en) | Methods and compositions for reducing the appearance of wrinkles | |
| JP6981664B2 (en) | Nourishing tonic | |
| JP2011195503A (en) | Protein glycation inhibitor | |
| KR20210058772A (en) | Composition for treating hair loss and promoting hair growth | |
| JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
| KR101965594B1 (en) | Composition for prevention of losing hair or promotion of growing hair comprising bean extract | |
| US10086028B2 (en) | Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry | |
| KR102353372B1 (en) | Composition for preventing hair loss or promoting hair growth comprising extract pupae of male bees | |
| KR102386120B1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
| JP2022078258A (en) | Endothelin converting enzyme inhibitor | |
| KR102129409B1 (en) | Composition for treating hair loss and promoting hair growth | |
| JP6076719B2 (en) | CGRP response promoter | |
| KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
| JP6607676B2 (en) | TRPV4 activator | |
| KR102709727B1 (en) | Composition for inhibiting growth of body hair comprising the Mallotus japonicus or the fraction thereof | |
| JP2014172849A (en) | Type i collagen production promoter | |
| KR102693535B1 (en) | Composition for inhibiting growth of body hair comprising the Eurya japonica or the fraction thereof | |
| JP6017259B2 (en) | Endothelin action inhibitor | |
| KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient | |
| JP2012149020A (en) | Skin whitening agent | |
| KR20150111793A (en) | Anti-inflammatory agent containing pulchellamin g | |
| KR20160024069A (en) | Composition for improving skin conditions comprising an extract of oriental melon stem or cucumber stem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |